BICYCLE THERAPEUTICS PLC

For the period ended Jun 30, 2025. Filed Aug 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 8, 2025

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Three Months Ended · · Six Months Ended
· · June 30, · · June 30,
· 2025 · 2024 · 2025 · 2024
Collaboration revenue	$2,920	$9,361	$12,897	$28,891
Operating expenses:
Research and development	71,029	40,059	130,087	74,923
General and administrative	18,493	15,949	39,616	32,331
Total operating expenses	89,522	56,008	169,703	107,254
Loss from operations	(86,602)	(46,647)	(156,806)	(78,363)
Other income (expense):
Interest and other income	7,473	7,774	15,887	13,398
Interest expense	(54)	(824)	(105)	(1,645)
Total other income, net	7,419	6,950	15,782	11,753
Net loss before income tax provision	(79,183)	(39,697)	(141,024)	(66,610)
(Benefit from) provision for income taxes	(231)	115	(1,318)	(235)
Net loss	$(78,952)	$(39,812)	$(139,706)	$(66,375)
Net loss per share, basic and diluted	$(1.14)	$(0.77)	$(2.02)	$(1.40)
Weighted average ordinary shares outstanding, basic and diluted	69,252,009	51,992,034	69,224,629	47,276,062

Comprehensive loss:
Net loss	$(78,952)	$(39,812)	$(139,706)	$(66,375)
Other comprehensive income (loss):
Foreign currency translation adjustment	(1,902)	(314)	(3,482)	212
Total comprehensive loss	$(80,854)	$(40,126)	$(143,188)	$(66,163)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.